Colorectal cancer (CRC) is the third most common diagnosed malignancy among both
sexes in the United States as well as in the European Union. While the incidence and …

Patient-derived xenograft (PDX) models are increasingly being used in oncology drug
development because they offer greater predictive value than traditional cell line models …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Background While it has been challenging to establish prostate cancer patient‐derived
xenografts (PDXs), with a take rate of 10‐40% and long latency time, multiple groups …

Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in
diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus …

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy.
The development of new CRPC treatment strategies is strongly impeded by the scarcity of …

Despite advances in understanding of ovarian cancer biology, the progress in translation of
research findings into new therapies is still slow. It is associated in part with limitations of …

Preclinical knowledge of dysregulated pathways and potential biomarkers for urological
cancers has undergone limited translation into the clinic. Moreover, the low approval rate of …

Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all
disciplines and medical specialties. Most endocrinologists, and especially those working in …

RNA polymerase (pol) III occurs in two forms, containing either the POLR3G subunit or the
related paralogue POLR3GL. Whereas POLR3GL is ubiquitous, POLR3G is enriched in …